

# THE 34<sup>TH</sup> ANNUAL PRACTICING PHYSICIAN'S APPROACH TO THE DIFFICULT HEADACHE PATIENT

MAR | 2021  
8 | to 2022

DISCLOSURE

## PROGRAM OVERVIEW

In the United States, 1.4% of all visits to office-based physicians are due to headache, which represents approximately 12 million physician visits in one year. According to recent studies, 8.7 million females and 2.6 million males in the US alone experience migraine. Existing and ongoing research activity in the field of headache has produced clinical data of which primary care providers should be cognizant in order to provide optimal care to headache sufferers. These data have significant implications for diagnosis and treatment and may challenge current assumptions about the role of healthcare professionals in the management of primary headache disorders. Practitioners should be knowledgeable about new findings concerning pharmacological agents used for the treatment of headache, including new formulations of existing medications and those recently available for headache management.

## LEARNING OBJECTIVES

After participating in this educational activity, participants should be better able to

1. Become familiar with differential diagnoses, comorbidities, and aspects of headache care related to primary headache disorders.
2. Determine the challenges and treatment protocols for post-traumatic headache.
3. Use effective therapeutic tools that address the gender-specific challenges of treating women with migraine.
4. Enhance knowledge of safety and efficacy of drug interactions in headache treatment and management.
5. Become aware of how to conduct research in the headache field.

## ACCREDITATION/DESIGNATION STATEMENTS

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Forefront Collaborative and Diamond Headache Clinic Research & Educational Foundation. Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

## ACCME

Forefront Collaborative designates this enduring activity for a maximum of 3.75 *AMA PRA Category 1 Credits*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

## AAFP

Application for CME credit has been filed with the American Academy of Family Physicians. Determination of credit is pending.

## CERTIFICATES

To receive your CME certificate or your certificate of participation, you **MUST** complete the Forefront Collaborative online evaluation form. You may access the evaluation form at <https://forefrontcollab.mededmanager.com/evaluation/number/54710>.

**The evaluation opens on Monday, March 8, 2021, and must be completed by Tuesday, March 8, 2022.**

- ▶ Your certificate will generate in a new tab immediately upon completion of the evaluation, so be ready to print and/or save your certificate at that time
- ▶ A copy of your certificate will be emailed to you upon completion of the evaluation as well as be available in the account you created and can be accessed at any time in your dashboard.



**THE 34<sup>TH</sup> ANNUAL  
PRACTICING PHYSICIAN'S APPROACH  
TO THE DIFFICULT HEADACHE PATIENT**

**MAR** | 2021  
**8** | to 2022

## UNLABELED USE DECLARATION

---

During their presentation, faculty may discuss unlabeled or investigational uses that are not approved for a commercial product. Faculty members are required to disclose this information to the audience when referring to an unlabeled or investigational use.

## STATEMENT OF DISCLOSURE AND INDEPENDENCE

---

Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all financial relationship(s) with ineligible companies.\* For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below as they were at the time of the event.

*\*The ACCME defines an ineligible company as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined ineligible company.*

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative.

## REVIEW COMMITTEE

---

In accordance with Forefront Collaborative policy, all content is reviewed by independent peer reviewers for balance, objectivity, and commercial bias. The review committee includes the following reviewers/editors: **Mark W. Green, MD, FAAN**, and **George J. Urban, MD**.

## FACULTY/PLANNING COMMITTEE DISCLOSURES

---

The following individuals have indicated that they have not had relationship(s) with ineligible companies in the last 24 months:

INDEPENDENT PEER REVIEWER: **Mark W. Green, MD, FAAN**

PLANNERS: **Jacquelyn Fernandez** and **Leah Johnson**

The following individuals have disclosed that they have had a financial relationship with an ineligible company in the past 24 months:

## FACULTY

---

### **Merle L. Diamond, MD**

**Consulting Fee:** Amgen, Eli Lilly, Lundbeck Pharmaceuticals, Promius Pharma, Teva

**Speakers Bureau:** Amgen, Eli Lilly, Lundbeck, Supernus Pharmaceuticals, Teva, Upsher-Smith

**Advisory Board:** Amgen, Asserzio Therapeutics, Axsome Therapeutics, Eli Lilly, Supernus Pharmaceuticals, Teva, Upsher-Smith, Lundbeck

**Contracted Research:** Allergan, Amgen, Eli Lilly, Lundbeck, Teva

# THE 34<sup>TH</sup> ANNUAL PRACTICING PHYSICIAN'S APPROACH TO THE DIFFICULT HEADACHE PATIENT

MAR | 2021  
8 | to 2022

## Wade M. Cooper, DO

**Consulting Fee:** Amgen, Dolor technologies, Eli Lilly, Teva

**Advisory Board:** Amgen, Eli Lilly, Teva

**Ownership Interest (excluding diversified mutual funds):** Dolor Technologies

## Deborah I. Friedman, MD, MPH

**Advisory Board:** Allergan, Biohaven Pharmaceuticals, Eli Lilly, HealthyWomen, Impel, Invex, Lundbeck, Revance Therapeutics, Satsuma Pharmaceuticals, Spinal CSF Leak Foundation, Teva Pharmaceuticals, Theranica, Zosano Pharma

**Contracted Research:** Allergan, Eli Lilly, Merck, Zosano Pharma

**Contributing Author:** MedLink Neurology, Medscape

**Editorial Board:** Neurology Reviews

**Board of Directors:** American Headache Society, Southern Headache Society

## Duren Michael Ready, MD, FAHS

**Speakers Bureau:** Amgen, Allergan, Biohaven Pharmaceuticals, Eli Lilly, Lundbeck, Teva Pharmaceuticals

**Advisory Board:** Allergan

**Board of Directors:** American Headache Society, Southern Headache Society

## Timothy R. Smith, MD, RPh

**Advisor/Consultant:** Alder/Lundbeck, Amgen, Allergan/Abbvie, Biohaven, Impel Neuropharma, Lilly, Nocira, Theranica, Vorso

**Speakers Bureau:** Amgen, Allergan/Abbvie, Biohaven, Lilly

**Clinical Trial Support:** Alder/Lundbeck, Allergan/Abbvie, Amgen, Biohaven, Boehringer Ingelheim, Charleston Labs, Electrocore, Impel Neuropharma, Lilly, Pfizer, Nocira, Novartis, Novo Nordisk, Satsuma, Teva, Theranica, Vorso

**Stockholder:** United Health Group

**Board of Directors:** National Headache Foundation

## INDEPENDENT PEER REVIEWER

---

### George Urban, MD

**Consulting Fee:** Allergan, Amgen, Biohaven, Lilly

**Speakers Bureau:** Allergan, Amgen, Lilly

**Contracted Research:** Amgen, Allergan and Lundbeck

## PLANNERS

---

### Konrad Kothmann

**Consulting Fee:** Allergan, Amgen, Lilly, Lundbeck, Novartis